- Report
- September 2023
- 180 Pages
Global
From €5237EUR$5,500USD£4,476GBP
- Clinical Trials
- August 2022
- 100 Pages
Global
From €1428EUR$1,500USD£1,221GBP
- Clinical Trials
- May 2022
- 120 Pages
Global
From €1904EUR$2,000USD£1,628GBP
- Report
- January 2022
- 200 Pages
Global
From €7141EUR$7,500USD£6,104GBP
- Report
- January 2022
- 200 Pages
Global
From €7141EUR$7,500USD£6,104GBP
- Report
- January 2022
- 200 Pages
Global
From €7141EUR$7,500USD£6,104GBP
- Report
- January 2022
- 60 Pages
Global
From €3761EUR$3,950USD£3,215GBP
- Report
- January 2022
- 60 Pages
Global
From €3761EUR$3,950USD£3,215GBP
- Report
- January 2022
- 60 Pages
Global
From €3761EUR$3,950USD£3,215GBP
- Clinical Trials
- May 2021
Global
From €1904EUR$2,000USD£1,628GBP
- Report
- August 2021
Europe
From €3256EUR$3,420USD£2,783GBP
- Report
- August 2021
Global
From €3799EUR$3,990USD£3,247GBP
- Report
- August 2022
Global
From €752EUR$790USD£643GBP
- Report
- August 2022
Global
From €752EUR$790USD£643GBP
- Report
- August 2022
United States
From €1847EUR$1,940USD£1,579GBP
- Clinical Trials
- February 2022
- 91 Pages
Global
From €2380EUR$2,500USD£2,035GBP
- Report
- January 2023
- 92 Pages
Global
From €4760EUR$5,000USD£4,069GBP
- Clinical Trials
- December 2021
- 90 Pages
Global
From €2380EUR$2,500USD£2,035GBP
- Drug Pipelines
- November 2020
- 114 Pages
Global
From €1904EUR$2,000USD£1,628GBP
- Report
- April 2022
- 64 Pages
Global
From €3332EUR$3,500USD£2,848GBP
Ataxia is a neurological disorder that affects the coordination of movement. Ataxia drugs are used to treat the symptoms of this disorder, which can include difficulty walking, speaking, and swallowing. These drugs are part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological and psychiatric disorders. Ataxia drugs are typically prescribed to improve coordination and balance, as well as to reduce the risk of falls.
Ataxia drugs are typically divided into two categories: symptomatic and disease-modifying. Symptomatic drugs are used to reduce the symptoms of ataxia, while disease-modifying drugs are used to slow the progression of the disorder. Common symptomatic drugs include benzodiazepines, anticholinergics, and anticonvulsants. Disease-modifying drugs include immunomodulators, gene therapy, and stem cell therapy.
Some companies in the Ataxia Drug market include AbbVie, Biogen, Merck, Novartis, and Pfizer. Show Less Read more